Company Encyclopedia
View More
name
Evolus
EOLS.US
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
4.514 T
EOLS.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking78/183
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE512.13%A
    • Profit Margin-20.49%D
    • Gross Margin66.47%A
  • Growth ScoreC
    • Revenue YoY15.10%B
    • Net Profit YoY-5.59%C
    • Total Assets YoY-4.62%D
    • Net Assets YoY-588.29%E
  • Cash ScoreC
    • Cash Flow Margin-488.07%E
    • OCF YoY15.10%B
  • Operating ScoreA
    • Turnover1.27A
  • Debt ScoreE
    • Gearing Ratio113.13%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Evolus, Inc. $EOLS Position Cut by Connor Clark & Lunn Investment Management Ltd.

    Connor Clark & Lunn Investment Management Ltd. reduced its stake in Evolus, Inc. by 85.7% in Q2, now holding 10,402 shares worth $96,000. Evolus' stock opened at $6.85, with a market cap of $444.02 million. Analysts have mixed ratings, with a consensus "Hold" and an average target price of $21.25. Evolus focuses on aesthetic products, offering Jeuveau for glabellar lines. The company reported a Q3 EPS of ($0.14), beating estimates by $0.05, with revenue of $68.97 million.

    Market Beat·
    US
    EOLS
    +0.89%
    Market Beat·
    US
    EOLS
    +0.89%

    Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

    Nov 14 (Reuters) - Evolus Inc:* EVOLUS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4) Source text: Further company coverage:

    Reuters·
    US
    EOLS
    +0.89%
    Reuters·
    US
    EOLS
    +0.89%

    Evolus Grants Stock Options and RSUs to New Hires Under 2023 Inducement Plan

    Evolus Inc. has granted stock options and RSUs to 13 new non-executive employees under the 2023 Inducement Incentive Plan. The stock options cover 17,871 shares at $6.56 per share, matching the closing price on November 7, 2025. Both stock options and RSUs vest over four years, with 25% vesting annually. Recipients must remain employed through each vesting date.

    Reuters·
    US
    EOLS
    +0.89%
    Reuters·
    US
    EOLS
    +0.89%

    Evolus (NASDAQ:EOLS) Posts Earnings Results, Misses Expectations By $0.10 EPS

    Evolus (NASDAQ:EOLS) reported earnings of ($0.24) per share, missing estimates by $0.10. The company had a negative net margin of 22.31% and a return on equity of -759.04%. Revenue was $68.97 million, exceeding expectations of $67.75 million. The stock rose $0.40 to $6.81, with a market cap of $440.47 million. Analysts have mixed ratings, with a consensus hold rating and a price target of $21.25. Recent insider transactions included a director buying 30,000 shares and a CMO selling 5,722 shares.

    Market Beat·
    US
    EOLS
    +0.89%
    Market Beat·
    US
    EOLS
    +0.89%

    Brookfield Renewable Corp reports results for the quarter ended September 30 - Earnings Summary

    Brookfield Renewable Corp reported a quarterly adjusted loss of 23 cents per share for the quarter ended September 30, an improvement from a loss of 32 cents in the same quarter last year. Revenue increased by 8.6% to $1.60 billion, surpassing analyst expectations of $1.58 billion. The company incurred a total loss of $120 million. Analysts maintain a "buy" rating on the stock, with a median 12-month price target of $39.00, which is about 10% below its last closing price of $42.91.

    Reuters·
    US
    BEPC
    +1.37%
    Reuters·
    US
    BEPC
    +1.37%
    © 2025 Longbridge｜Disclaimer